Legend Biotech announced that its product CARVYKTI generated approximately $710 million in net trade sales during the quarter ended September 30, 2026. This figure is based on information provided by collaboration partner Janssen and has not been independently verified or audited by Legend Biotech's accountants. The company operates in the biotechnology industry, focusing on the development of immunotherapies for cancer treatment.
